NASDAQ:ARQT Arcutis Biotherapeutics Q3 2025 Earnings Report $20.08 +0.27 (+1.36%) Closing price 04:00 PM EasternExtended Trading$20.08 +0.01 (+0.02%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Arcutis Biotherapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.09Beat/MissN/AOne Year Ago EPSN/AArcutis Biotherapeutics Revenue ResultsActual RevenueN/AExpected Revenue$86.69 millionBeat/MissN/AYoY Revenue GrowthN/AArcutis Biotherapeutics Announcement DetailsQuarterQ3 2025Date10/28/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Arcutis Biotherapeutics Earnings HeadlinesArcutis Biotherapeutics (NASDAQ:ARQT) Earns Sell (E+) Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Arcutis Biotherapeutics (ARQT)October 8, 2025 | theglobeandmail.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.October 23 at 2:00 AM | Banyan Hill Publishing (Ad)Arcutis Biotherapeutics stock rises after FDA approves eczema cream for young childrenOctober 6, 2025 | investing.comFDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5October 6, 2025 | markets.businessinsider.comArcutis Biotherapeutics Shares Rise After FDA Approves Eczema Cream for Young ChildrenOctober 6, 2025 | msn.comSee More Arcutis Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcutis Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your email. Email Address About Arcutis BiotherapeuticsArcutis Biotherapeutics (NASDAQ:ARQT) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options. In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies. Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.View Arcutis Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla’s Earnings Review: Does the Juice Justify the Squeeze?Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings Signal Upcoming Earnings Sanofi (10/24/2025)ENI (10/24/2025)General Dynamics (10/24/2025)HCA Healthcare (10/24/2025)ICICI Bank (10/24/2025)Illinois Tool Works (10/24/2025)Coca Cola Femsa (10/24/2025)NatWest Group (10/24/2025)Procter & Gamble (10/24/2025)Cadence Design Systems (10/27/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
